Citigroup
ADPT icon

Citigroup’s Adaptive Biotechnologies ADPT Stock Holding History

Citigroup’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Buy
104,876
+86,565
+473% +$1.33M ﹤0.01% 2848
2026
Q1 		$254K Sell
18,311
-5,697
-24% -$90.8K ﹤0.01% 3893
2025
Q4 		$390K Sell
24,008
-7,697
-24% -$126K ﹤0.01% 3697
2025
Q3 		$474K Sell
31,705
-34,986
-52% -$426K ﹤0.01% 3608
2025
Q2 		$777K Sell
66,691
-24,106
-27% -$219K ﹤0.01% 3338
2025
Q1 		$675K Sell
90,797
-8,815
-9% -$67.8K ﹤0.01% 3516
2024
Q4 		$597K Sell
99,612
-8,929
-8% -$49.2K ﹤0.01% 3705
2024
Q3 		$556K Buy
108,541
+47,535
+78% +$207K ﹤0.01% 3662
2024
Q2 		$221K Sell
61,006
-79,916
-57% -$254K ﹤0.01% 3831
2024
Q1 		$452K Buy
140,922
+114,571
+435% +$443K ﹤0.01% 3643
2023
Q4 		$129K Buy
26,351
+19,504
+285% +$89K ﹤0.01% 4101
2023
Q3 		$37.3K Sell
6,847
-37,566
-85% -$248K ﹤0.01% 4225
2023
Q2 		$298K Buy
44,413
+34,335
+341% +$255K ﹤0.01% 3684
2023
Q1 		$89K Sell
10,078
-2,650
-21% -$23.4K ﹤0.01% 4069
2022
Q4 		$97.2K Sell
12,728
-1,429
-10% -$11.1K ﹤0.01% 4035
2022
Q3 		$101K Sell
14,157
-11,447
-45% -$108K ﹤0.01% 4087
2022
Q2 		$207K Sell
25,604
-2,771
-10% -$24.4K ﹤0.01% 3833
2022
Q1 		$394K Buy
28,375
+4,047
+17% +$63.6K ﹤0.01% 3661
2021
Q4 		$683K Sell
24,328
-5,848
-19% -$179K ﹤0.01% 3590
2021
Q3 		$1.03M Sell
30,176
-5,270
-15% -$191K ﹤0.01% 3066
2021
Q2 		$1.45M Buy
35,446
+9,655
+37% +$375K ﹤0.01% 2938
2021
Q1 		$1.04M Sell
25,791
-4,086
-14% -$221K ﹤0.01% 2956
2020
Q4 		$1.77M Sell
29,877
-1,461
-5% -$75.3K ﹤0.01% 2977
2020
Q3 		$1.52M Sell
31,338
-2,254
-7% -$94.7K ﹤0.01% 2908
2020
Q2 		$1.63M Sell
33,592
-106,842
-76% -$3.9M ﹤0.01% 3046
2020
Q1 		$3.9M Buy
140,434
+13
+0% +$363 ﹤0.01% 1883
2019
Q4 		$4.2M Buy
140,421
+92,486
+193% +$2.66M ﹤0.01% 2178
2019
Q3 		$1.48M Buy
+47,935
New +$1.96M ﹤0.01% 3192

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Citigroup's ADPT Position: Q2 2026 in Review

Citigroup increased its Adaptive Biotechnologies (ADPT) stake by 473% in Q2 2026, buying an estimated $1.33M and bringing the position to 104,876 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Citigroup first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $4.2M in Q4 2019. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Citigroup held 104,876 shares of Adaptive Biotechnologies worth $2.25M as of Q2 2026.
  • Citigroup bought 86,565 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.33M.
  • Adaptive Biotechnologies made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2848 holding.
  • Citigroup first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • Citigroup's Adaptive Biotechnologies position peaked at $4.2M in Q4 2019.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.